The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases.

Humans Male Prostatic Neoplasms / therapy Salvage Therapy

Journal

European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661

Informations de publication

Date de publication:
03 2021
Historique:
received: 26 10 2020
revised: 19 11 2020
accepted: 10 12 2020
pubmed: 3 1 2021
medline: 31 3 2022
entrez: 2 1 2021
Statut: ppublish

Résumé

Optimal local treatment for nodal oligorecurrent prostate cancer is unknown. The randomized phase 2 PEACE V-STORM trial will explore the best treatment approach in this setting. Early results on the acute toxicity profile are projected to be published in quarter 3, 2021.

Identifiants

DOI: 10.1016/j.euf.2020.12.010 PMID: 33386290
pubmed: 33386290
pii: S2405-4569(20)30312-6
doi: 10.1016/j.euf.2020.12.010
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT03569241']

Types de publication

Clinical Trial, Phase II Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

241-244

Informations de copyright

Copyright © 2020 European Association of Urology. All rights reserved.

Auteurs

Thomas Zilli (T)

Department of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland. Electronic address: thomas.zilli@hcuge.ch.

Piet Dirix (P)

Department of Radiation Oncology, Iridium Kankernetwerk, Antwerp, Belgium; University of Antwerp, Faculty of Medicine and Health Sciences, Antwerp, Belgium.

Reino Heikkilä (R)

Department of Oncology, Oslo University Hospital, Oslo, Norway.

Nick Liefhooghe (N)

Department of Radiation Oncology, AZ Groeninge, Kortrijk, Belgium.

Shankar Siva (S)

Epworth Healthcare and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.

Alfonso Gomez-Iturriaga (A)

Biocruces Health Research Institute, Cruces University Hospital, Barakaldo, Spain.

Wouter Everaerts (W)

Department of Development and Regeneration, KU Leuven, Leuven, Belgium.

François Otte (F)

Department of Radiation Oncology, Jules Bordet Institute and Hôpital Erasme, University Clinics of Brussels, Université Libre de Bruxelles, Brussels, Belgium.

Mohamed Shelan (M)

Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Carole Mercier (C)

Department of Radiation Oncology, Iridium Kankernetwerk, Antwerp, Belgium; University of Antwerp, Faculty of Medicine and Health Sciences, Antwerp, Belgium.

Vérane Achard (V)

Department of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland.

Kristian Thon (K)

Department of Oncology, Oslo University Hospital, Oslo, Norway.

Karin Stellamans (K)

Department of Radiation Oncology, AZ Groeninge, Kortrijk, Belgium.

Daniel Moon (D)

Royal Melbourne Clinical School, University of Melbourne, Melbourne, Australia.

Antonio Conde-Moreno (A)

Department of Radiation Oncology, Hospital Universitari i Politècnic la Fe, Valencia, Spain.

Alexandros Papachristofilou (A)

Department of Radiotherapy and Radiation Oncology, University Hospital Basel, Basel, Switzerland.

Marta Scorsetti (M)

Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Hospital IRCSS, Rozzano, Italy.

Matthias Gückenberger (M)

Department of Radiation Oncology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.

Filip Ameye (F)

Department of Urology, AZ Maria-Middelares, Ghent, Belgium.

Almudena Zapatero (A)

Department of Radiation Oncology, University Hospital La Princesa, Madrid, Spain.

Lien Van De Voorde (L)

Department of Radiation Oncology, AZ St-Lucas, Ghent, Belgium.

Fernando López Campos (F)

Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.

Felipe Couñago (F)

Department of Radiation Oncology, University Hospital Quironsalud, Universidad Europea de Madrid, Madrid, Spain.

Maud Jaccard (M)

Department of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland.

An Spiessens (A)

Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium.

Isabelle Semac (I)

Department of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland.

Frederik Vanhoutte (F)

Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium.

Els Goetghebeur (E)

Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium.

Dries Reynders (D)

Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium.

Piet Ost (P)

Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium. Electronic address: piet.ost@ugent.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The Multicenter, Randomized, Phase 2 PEACE...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › The Multicenter, Randomized, Phase 2 PEACE...
questionsmedicales.fr › Thérapeutique › Thérapie de rattrapage › The Multicenter, Randomized, Phase 2 PEACE...